Genmab A/S (GMAB) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.

Do insiders and institutionals have more ownership in ALNY or GMAB?

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, ALNY or GMAB?

Alnylam Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

Which has higher valuation & earnings, ALNY or GMAB?

Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$1.83B	10.00	-$440.24M	-$3.56	-40.78
Genmab A/S	$2.39B	7.84	$631.91M	$0.96	29.51

Is ALNY or GMAB more profitable?

Genmab A/S has a net margin of 26.50% compared to Genmab A/S's net margin of -24.08%. Alnylam Pharmaceuticals' return on equity of 18.06% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-24.08%	N/A	-12.18%
Genmab A/S	26.50%	18.06%	16.13%

Does the MarketBeat Community prefer ALNY or GMAB?

Alnylam Pharmaceuticals received 945 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 76.16% of users gave Alnylam Pharmaceuticals an outperform vote while only 60.52% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1086 76.16%	Underperform Votes 340 23.84%
Genmab A/S	Outperform Votes 141 60.52%	Underperform Votes 92 39.48%

Does the media prefer ALNY or GMAB?

In the previous week, Alnylam Pharmaceuticals and Alnylam Pharmaceuticals both had 9 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.78 beat Genmab A/S's score of 0.65 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend ALNY or GMAB?

Alnylam Pharmaceuticals currently has a consensus price target of $216.12, suggesting a potential upside of 48.88%. Genmab A/S has a consensus price target of $48.50, suggesting a potential upside of 71.20%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Genmab A/S is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.56
Genmab A/S	3 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Genmab A/S beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks.